- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Comprehensive analysis for genomic features of stem cell-like hepatocellular carcinoma (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2037; We identified subtype-specific serum and tissue biomarkers for the stem cell-like subtypes and precise therapeutic strategies for each subtype regarding immunotherapy and molecular-targeted treatment. Our findings may offer the theoretical foundation of biomarker-based clinical trials for new therapeutic approaches to resectable early-stage HCC patients.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial primary completion date, Metastases: Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma (clinicaltrials.gov) - May 14, 2020 P1, N=20, Active, not recruiting, These differences may have contributed to the observed variation in results between the 2 studies. Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2020 --> Oct 2019
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. (Pubmed Central) - May 14, 2020 No significant differences were observed in median ΔSMI between patients with and without progressive disease (-2.35 and -1.1 cm2/m2/months, respectively), albumin-bilirubin grade 1 and 2 group disease (-1.7 and -1.5 cm2/m2/months, respectively), and relative dose intensity ≤80 and >80 (-1.8 and -1.2 cm2/m2/months, respectively). This report demonstrated that patients receiving TKI treatment experienced a significant loss of skeletal muscle mass regardless of disease progression, hepatic reserve, or which TKI (sorafenib or lenvatinib) they received.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal: Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape. (Pubmed Central) - May 13, 2020 Positioning of these immunotherapies in the landscape may or may not have impacts upon sequencing of all of the available therapies. Further studies are ongoing investigating such sequencing questions, in addition to more novel agents to combat this devastating disease.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_255; P3 Legal entity responsible for the study Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- |||||||||| Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Multikinase Inhibitor Treatment in Thyroid Cancer. (Pubmed Central) - May 6, 2020 The objective of this review is to give an update on MKI treatment (lenvatinib, sorafenib, sunitinib, cabozantinib, pazopanib, vandetanib) of thyroid cancer, regarding its efficacy and safety profile...The AEs are often more severe in patients with high efficacy of MKIs, which could indicate a correlation. Taken together, the novel therapeutic regimen with MKIs has shown favorable results in otherwise treatment-resistant thyroid cancer.
- |||||||||| Afinitor (everolimus) / Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma (RCC). (Poster Board 136) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1027; P1b/2 Within Study 205, lenvatinib+everolimus resulted in a statistically significant and clinically important gain in Q-TWiST vs everolimus alone. Research Funding: Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- |||||||||| Afinitor (everolimus) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes. (Poster Board 132) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1023; These data provide contemporary benchmarks for OS that may be used for patient counseling and trial design. *Sunitinib, Pazopanib, Cabozantinib †Sunitinib, Pazopanib, Cabozantinib, Axitinib, Lenvatinib NR = Not Reached Research Funding: None
|